Fluenz (influenza vaccine (live attenuated, nasal))
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (live attenuated, nasal)
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Influenza, Human
- CHMP opinion
- Tue 21 May 2024
- EU approval
- Mon 03 Jun 2024
- Application
- EMEA/H/C/006514
- ATC
- J07BB03
- Official record
- www.ema.europa.eu
Indication
Fluenz is indicated for active immunisation for the prevention of influenza disease in children and adolescents from 2 years to less than 18 years of age.Fluenz should be used in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fluenz Tetra Withdrawn · AstraZeneca AB
- 🇪🇺 Fluenz Withdrawn · MedImmune LLC
Follow Fluenz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.